Treatment.com AI Inc. Secures Significant Funding Through Private Placement
Treatment.com AI Inc. (CSE: TRUE; OTC: TREIF; FFA: 939) has recently achieved a notable milestone by closing a private placement that exceeded expectations. The company has raised an impressive total of $1,954,074 through the issuance of special warrants and units, marking a significant step in its ongoing growth journey.
Details of the Private Placement Offering
In this offering, Treatment.com AI Inc. successfully sold 2,138,766 special warrants priced at $0.75 each, generating gross proceeds of approximately $1,604,074.50. Additionally, the company sold 466,666 units, also at $0.75 each, resulting in an additional $349,999.50. This financing round showcased strong investor confidence, with the oversubscription indicating a high demand for the shares.
Structure of the Securities Involved
Each unit offered in the private placement consists of one common share and one-half of a share purchase warrant. This means that for each whole warrant, a holder can exercise their right to purchase an additional share at the price of $1.00 within a two-year period from the issuance date.
Conversion and Hold Period Details
Importantly, the special warrants will automatically convert into units without further payment on the conversion date. This date is defined as the earlier of either three business days after a specific prospectus supplement is filed or four months and one day from the issue date. Additionally, the securities issued are subject to a statutory hold period, ensuring compliance with applicable legislation.
Company Leadership Insights
CEO Dr. Essam Hamza expressed enthusiasm regarding the investors' response, stating, "We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription. This money will help expedite our aggressive growth plans over the next year." His statement reflects the company’s ongoing commitment to leveraging this funding to further enhance its operational capacity.
Use of Funds and Future Plans
The proceeds from this offering are intended primarily for working capital, allowing Treatment.com AI Inc. to invest strategically in various growth initiatives. The company aims to expand its capabilities and enhance the scope of its operations, signaling a promising outlook for its stakeholders.
About Treatment.com AI Inc.
Treatment.com AI is committed to revolutionizing healthcare by utilizing artificial intelligence alongside established clinical practices. The company has created a comprehensive AI engine, known as the Global Library of Medicine (GLM), which offers a wealth of clinically validated information. This platform, designed with input from healthcare professionals worldwide, supports medical practitioners by reducing administrative tasks and improving patient interaction quality.
Engagement with Healthcare Professionals
The GLM includes around 10,000 expert medical reviews, enabling healthcare providers to make informed decisions quickly. By supplying recommended tests, x-rays, and billing codes, Treatment.com AI is not only streamlining processes for doctors and nurses but also aiming to benefit underrepresented communities by ensuring equitable access to quality healthcare.
Investor Relations and Communication Channels
For more information or inquiries, stakeholders can contact Treatment.com AI Inc. directly. Dr. Essam Hamza, the CEO, can be reached at [ehamza@treatment.com](mailto:ehamza@treatment.com) for further details. The company also offers media contact at [media@treatment.com](mailto:media@treatment.com).
Frequently Asked Questions
What is the purpose of the funds raised in the offering?
The funds are primarily intended for working capital and support the company's various growth initiatives.
How was the recent funding round received by investors?
The offering was oversubscribed, showcasing strong investor interest and confidence in the company's future growth prospects.
What is included in each unit offered in the placement?
Each unit consists of one common share and one-half of a share purchase warrant, offering investors a structured investment opportunity.
What is the Global Library of Medicine (GLM)?
The GLM is a comprehensive AI-powered platform providing healthcare professionals with clinically validated information to improve patient care.
Who can investors contact for more information?
Investors can reach out to Dr. Essam Hamza via email at [ehamza@treatment.com](mailto:ehamza@treatment.com) for any inquiries related to the company.
